Standard

Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. / Ouweneel, Dagmar M.; Eriksen, Erlend; Sjauw, Krischan D. et al.

In: Journal of the American College of Cardiology, Vol. 69, No. 3, 2017, p. 278-287.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

Author

Ouweneel, Dagmar M. ; Eriksen, Erlend ; Sjauw, Krischan D. et al. / Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. In: Journal of the American College of Cardiology. 2017 ; Vol. 69, No. 3. pp. 278-287.

BibTeX

@article{0c9443d6a6214b64859ca3ce9a7f8334,
title = "Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction",
abstract = "Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high. Short-term mechanical circulatory support devices acutely improve hemodynamic conditions. The aim of this study was to determine whether a new percutaneous mechanical circulatory support (pMCS) device (Impella CP, Abiomed, Danvers, Massachusetts) decreases 30-day mortality when compared with an intra-aortic balloon pump (IABP) in patients with severe shock complicating AMI. In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicating AMI were assigned to pMCS (n = 24) or IABP (n = 24). Severe CS was defined as systolic blood pressure <90 mm Hg or the need for inotropic or vasoactive medication and the requirement for mechanical ventilation. The primary endpoint was 30-day all-cause mortality. At 30 days, mortality in patients treated with either IABP or pMCS was similar (50% and 46%, respectively; hazard ratio with pMCS: 0.96; 95% confidence interval: 0.42 to 2.18; p = 0.92). At 6 months, mortality rates for both pMCS and IABP were 50% (hazard ratio: 1.04; 95% confidence interval: 0.47 to 2.32; p = 0.923). In this explorative randomized controlled trial involving mechanically ventilated patients with CS after AMI, routine treatment with pMCS was not associated with reduced 30-day mortality compared with IABP. (IMPRESS in Severe Shock; NTR3450)",
author = "Ouweneel, {Dagmar M.} and Erlend Eriksen and Sjauw, {Krischan D.} and {van Dongen}, {Ivo M.} and Alexander Hirsch and Packer, {Erik J. S.} and Vis, {M. Marije} and Wykrzykowska, {Joanna J.} and Koch, {Karel T.} and Jan Baan and {de Winter}, {Robbert J.} and Piek, {Jan J.} and Lagrand, {Wim K.} and {de Mol}, {Bas A. J. M.} and Tijssen, {Jan G. P.} and Henriques, {Jos{\'e} P. S.}",
year = "2017",
doi = "10.1016/j.jacc.2016.10.022",
language = "English",
volume = "69",
pages = "278--287",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

RIS

TY - JOUR

T1 - Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction

AU - Ouweneel, Dagmar M.

AU - Eriksen, Erlend

AU - Sjauw, Krischan D.

AU - van Dongen, Ivo M.

AU - Hirsch, Alexander

AU - Packer, Erik J. S.

AU - Vis, M. Marije

AU - Wykrzykowska, Joanna J.

AU - Koch, Karel T.

AU - Baan, Jan

AU - de Winter, Robbert J.

AU - Piek, Jan J.

AU - Lagrand, Wim K.

AU - de Mol, Bas A. J. M.

AU - Tijssen, Jan G. P.

AU - Henriques, José P. S.

PY - 2017

Y1 - 2017

N2 - Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high. Short-term mechanical circulatory support devices acutely improve hemodynamic conditions. The aim of this study was to determine whether a new percutaneous mechanical circulatory support (pMCS) device (Impella CP, Abiomed, Danvers, Massachusetts) decreases 30-day mortality when compared with an intra-aortic balloon pump (IABP) in patients with severe shock complicating AMI. In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicating AMI were assigned to pMCS (n = 24) or IABP (n = 24). Severe CS was defined as systolic blood pressure <90 mm Hg or the need for inotropic or vasoactive medication and the requirement for mechanical ventilation. The primary endpoint was 30-day all-cause mortality. At 30 days, mortality in patients treated with either IABP or pMCS was similar (50% and 46%, respectively; hazard ratio with pMCS: 0.96; 95% confidence interval: 0.42 to 2.18; p = 0.92). At 6 months, mortality rates for both pMCS and IABP were 50% (hazard ratio: 1.04; 95% confidence interval: 0.47 to 2.32; p = 0.923). In this explorative randomized controlled trial involving mechanically ventilated patients with CS after AMI, routine treatment with pMCS was not associated with reduced 30-day mortality compared with IABP. (IMPRESS in Severe Shock; NTR3450)

AB - Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high. Short-term mechanical circulatory support devices acutely improve hemodynamic conditions. The aim of this study was to determine whether a new percutaneous mechanical circulatory support (pMCS) device (Impella CP, Abiomed, Danvers, Massachusetts) decreases 30-day mortality when compared with an intra-aortic balloon pump (IABP) in patients with severe shock complicating AMI. In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicating AMI were assigned to pMCS (n = 24) or IABP (n = 24). Severe CS was defined as systolic blood pressure <90 mm Hg or the need for inotropic or vasoactive medication and the requirement for mechanical ventilation. The primary endpoint was 30-day all-cause mortality. At 30 days, mortality in patients treated with either IABP or pMCS was similar (50% and 46%, respectively; hazard ratio with pMCS: 0.96; 95% confidence interval: 0.42 to 2.18; p = 0.92). At 6 months, mortality rates for both pMCS and IABP were 50% (hazard ratio: 1.04; 95% confidence interval: 0.47 to 2.32; p = 0.923). In this explorative randomized controlled trial involving mechanically ventilated patients with CS after AMI, routine treatment with pMCS was not associated with reduced 30-day mortality compared with IABP. (IMPRESS in Severe Shock; NTR3450)

U2 - 10.1016/j.jacc.2016.10.022

DO - 10.1016/j.jacc.2016.10.022

M3 - Article

C2 - 27810347

VL - 69

SP - 278

EP - 287

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -

ID: 3009908